Next Article in Journal
Neuropathic Pain in Pancreatic Cancer: An Update of the Last Five Years
Previous Article in Journal
Foremost Concepts in Mechanisms of De Novo Post-Liver Transplantation Malignancy
Commentary

Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary

Department of Biomedical Sciences, Mercer University School of Medicine, Columbus, GA 31209, USA
Academic Editors: Gaetano Luglio and Alessandro Granito
Gastroenterol. Insights 2021, 12(3), 293-301; https://0-doi-org.brum.beds.ac.uk/10.3390/gastroent12030026
Received: 7 May 2021 / Revised: 10 June 2021 / Accepted: 21 June 2021 / Published: 24 June 2021
(This article belongs to the Topic Inflammatory Bowel Disease (IBD): Mechanism to Management)
This commentary summarizes a collection of key references published within the last ten years, and identifies pharmacologic research directions to improve treatment access and success through greater biosimilar or “follow-on” biologic utilization combined with other targeted small molecule agents that possess unique pathophysiologic mechanisms for inflammatory bowel diseases (IBD) in adult and pediatric patients. Since they are not identical to the originator or reference biologic agent, all biosimilars are not generically equivalent. However, in the US and other countries, they are considered therapeutically interchangeable if the manufacturer has demonstrated no clinically meaningful differences from the reference product. Comparisons of different clinical initiation and switching scenarios are discussed with reference to interchangeability, immunogenicity, nocebo effect, cost effectiveness, and time courses for discontinuation rates. View Full-Text
Keywords: antibody; biologic; biosimilar; Crohn disease; guideline; inflammatory bowel disease; molecule; small; monitoring; monoclonal; nocebo; pediatric; switching; drug; ulcerative colitis antibody; biologic; biosimilar; Crohn disease; guideline; inflammatory bowel disease; molecule; small; monitoring; monoclonal; nocebo; pediatric; switching; drug; ulcerative colitis
MDPI and ACS Style

Parrish, R.H., II. Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary. Gastroenterol. Insights 2021, 12, 293-301. https://0-doi-org.brum.beds.ac.uk/10.3390/gastroent12030026

AMA Style

Parrish RH II. Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary. Gastroenterology Insights. 2021; 12(3):293-301. https://0-doi-org.brum.beds.ac.uk/10.3390/gastroent12030026

Chicago/Turabian Style

Parrish, Richard H., II. 2021. "Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary" Gastroenterology Insights 12, no. 3: 293-301. https://0-doi-org.brum.beds.ac.uk/10.3390/gastroent12030026

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop